Biogen Inc. (BIIB) Sees Unusually-High Trading Volume
Biogen Inc. (NASDAQ:BIIB) saw unusually-high trading volume on Friday . Approximately 1,463,058 shares changed hands during trading, an increase of 13% from the previous session’s volume of 1,293,025 shares.The stock last traded at $313.39 and had previously closed at $306.03.
BIIB has been the subject of a number of recent analyst reports. Piper Jaffray Cos. restated a “neutral” rating on shares of Biogen in a research report on Wednesday, August 3rd. Morgan Stanley raised their price objective on shares of Biogen from $383.00 to $385.00 and gave the company an “overweight” rating in a research report on Thursday, July 21st. Jefferies Group restated a “buy” rating and issued a $317.00 price objective on shares of Biogen in a research report on Wednesday, July 13th. Credit Suisse Group AG restated a “hold” rating and issued a $312.00 price objective on shares of Biogen in a research report on Friday, July 22nd. Finally, BMO Capital Markets restated a “market perform” rating and issued a $287.00 price objective on shares of Biogen in a research report on Sunday, July 24th. Ten analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $345.89.
The firm has a 50 day moving average price of $302.07 and a 200 day moving average price of $271.44. The firm has a market capitalization of $68.71 billion and a PE ratio of 18.32.
Biogen (NASDAQ:BIIB) last released its earnings results on Thursday, July 21st. The biotechnology company reported $5.21 EPS for the quarter, beating the consensus estimate of $4.69 by $0.52. The business had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.79 billion. During the same period in the prior year, the company earned $4.22 earnings per share. The firm’s revenue for the quarter was up 11.7% on a year-over-year basis. Equities analysts anticipate that Biogen Inc. will post $20.11 earnings per share for the current year.
In related news, CEO George A. Scangos sold 157 shares of the company’s stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $280.00, for a total value of $43,960.00. Following the completion of the sale, the chief executive officer now owns 54,779 shares in the company, valued at approximately $15,338,120. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Adam Koppel sold 555 shares of the company’s stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $290.00, for a total transaction of $160,950.00. Following the completion of the sale, the executive vice president now owns 2,402 shares of the company’s stock, valued at approximately $696,580. The disclosure for this sale can be found here.
Biogen Inc, formerly Biogen Idec Inc, is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.